The FDA has approved Requip XL (ropinirole extended-release tablets, from GlaxoSmithKline) for the treatment of idiopathic Parkinson’s disease. Requip XL has a tri-layer formulation intended to provide continuous delivery of ropinirole over a 24 hour period. Results from a clinical study showed that Requip XL significantly reduced “off” time by an average of 2.1 hours per day from baseline compared to a reduction of 0.4 hours per day for placebo.
Requip XL is expected to be available in pharmacies in mid-July 2008.
For more information call (888) 825-5249 or visit www.gsk.com.